SB 25-048: Diabetes Prevention & Obesity Treatment Act - Colorado

Revised (05/05/2025) → PA1 (04/29/2025) · 6 edits

MODERATE

This bill was amended to expand coverage requirements from large group health plans to all individual and group health plans, while adding specific definitions for FDA-approved anti-obesity medications and GLP-1 medications. The revision also clarifies that carriers are not required to offer coverage if premiums would not cover expected benefits, and adds detailed definitions for intensive behavioral therapy and other treatment components.

Scope change

Expanded from large group health plans to all individual and group health plans issued or renewed in Colorado

SCOPE

Changed applicability from large group health plans to all individual and group health plans

DEFINITION

Added specific definitions for FDA-approved anti-obesity medication and FDA-approved GLP-1 medication

Added detailed definition for intensive behavioral or lifestyle therapy as evidence-based multi-component intervention

REQUIREMENT

Added requirement to offer coverage for FDA-approved anti-obesity medications including at least one GLP-1 medication

Added provision that carriers are not required to offer coverage if premiums would not cover expected benefits

ENFORCEMENT

Added authority for commissioner to adopt rules to implement the new subsection

Rerevised (05/06/2025) → Revised (05/05/2025) · 3 edits

MINOR

The bill was revised to update its status from 'Rerevised' to 'Revised' following amendments adopted on second reading in the Second House. The substantive content of the bill remains unchanged, with only formatting and versioning updates applied to reflect its legislative progress.

TECHNICAL

Header text updated from 'REREVISED' to 'REVISED' and amended language to specify that the version includes all amendments adopted on second reading in the Second House.

Removed House sponsorship names (Brown and Mabrey, Bacon, Boesenecker, Duran, Gilchrist, Jackson, Lieder, Lindsay, Lukens, McCormick, Phillips, Ricks, Rutinel, Woodrow) that were previously listed.

Removed the '3rd Reading Unamended' date stamp and House committee designation from the header section.

PA2 (05/03/2025) → Rerevised (05/06/2025) · 3 edits

MINOR

The bill was revised to incorporate all amendments adopted by the Second House, expanding the list of House sponsors and updating the legislative status to reflect the 3rd Reading Unamended stage. The substantive content regarding diabetes prevention and obesity treatment requirements remains consistent, though some formatting and section numbering were adjusted during the revision process.

Scope change

The bill's scope remains focused on requiring large group health benefit plans to offer coverage for FDA-approved anti-obesity medications, including GLP-1 medications, but no substantive policy scope changes were identified in this revision.

TECHNICAL

Added new House sponsors (Bacon, Boesenecker, Duran, Gilchrist, Jackson, Lieder, Lindsay, Lukens, McCormick, Phillips, Ricks, Rutinel, Woodrow) to the House sponsorship section.

Updated legislative status headers from 'PREAMENDED' to 'REREVISED' and added reading stage information (3rd Reading Unamended, Amended 2nd Reading).

Removed committee amendment disclaimer text that indicated the version included unadopted committee amendments.

Final Act (05/15/2025) → PA2 (05/03/2025) · 5 edits

MODERATE

This bill was reorganized and reformatted from a draft version to a final act version, with the main substantive policy content remaining largely the same. The bill mandates private insurance coverage for obesity and pre-diabetes treatment, including medications, nutrition therapy, and surgery. It also requires the state to seek federal authorization for Medicaid coverage of these treatments.

Scope change

The bill's scope remains focused on requiring private insurance coverage and seeking federal Medicaid authorization for obesity and pre-diabetes treatments, with no substantive changes to the policy requirements.

TECHNICAL

The document was reformatted from a draft version with committee notes to a final act version with proper legislative formatting, including bill numbers, sponsor lists, and committee assignments.

Added header information including session details (First Regular Session, Seventy-fifth General Assembly) and committee assignments for both Senate and House.

Removed draft notes and placeholder text about bill preparation and signatures, replacing them with official legislative formatting.

Reorganized the bill text to follow standard Colorado legislative format with proper section numbering and line numbers.

Added a bill summary section explaining the bill's purpose in plain language for non-lawyers.

Engrossed (04/29/2025) → Reengrossed (04/30/2025) · 4 edits · Apr 30, 2025

MODERATE

This bill was reengrossed to add more sponsors and update the title page information. The substantive policy changes focus on clarifying the language around obesity and pre-diabetes treatment coverage for large group health plans, expanding the definition of covered therapies, and adding specific definitions for behavioral interventions.

Scope change

The bill's scope remains focused on large group health plans in Colorado, but the language was refined to clarify applicability and expand the list of covered treatments.

REQUIREMENT

Changed 'health plans' to 'health benefit plans' in the mandatory coverage section for greater precision.

Reordered the list of covered treatments to place 'chronic disease of obesity' before 'pre-diabetes' for clarity.

Added 'Medical Nutrition Therapy' to the list of covered treatments for obesity and pre-diabetes.

DEFINITION

Added new definitions for 'Intensive Behavioral or Lifestyle Therapy' to specify it must be evidence-based and multi-component.

Introduced (01/08/2025) → Engrossed (04/29/2025) · 4 edits · Apr 30, 2025

MODERATE

This bill was amended to narrow the scope of mandatory insurance coverage for obesity treatment. The Senate changed the requirement from applying to all individual and group health plans to only large group health plans, and removed the mandate for plans to offer anti-obesity medications if they would not cover expected benefits. The definition of anti-obesity medication was updated to specifically include FDA-approved GLP-1 medications.

Scope change

The bill's scope was narrowed from applying to all individual and group health plans to only large group health plans.

SCOPE

Mandatory coverage for obesity treatment now applies only to large group health plans instead of all individual and group health plans.

REQUIREMENT

Removed the requirement that plans must offer anti-obesity medication coverage even if premiums would not cover expected benefits.

Removed the requirement that coverage for obesity treatment must not be different from coverage for other illnesses regarding copayments, deductibles, and coinsurance.

DEFINITION

Added specific definition for 'FDA-approved GLP-1 medication' as a type of anti-obesity medication.

Diabetes Prevention & Obesity Treatment Act

What changed between versions

How they voted

Actions timeline

Sponsors